Current position:Home > Selling > Evista (Raloxifene Hydrochloride)

Evista (Raloxifene Hydrochloride)

  • CAS No.: 82640-04-8
  • Purity: 99%
  • Min quantity: 1000 Kilograms
  • Price: USD 1~1000/Kilograms
  • Place of Orign: jinan,Shandong,China
Ms.Lillian Cao

Supplier Details

View the Seller's Store
Product Details
Company Profile

Item specifics

  • Product Name.:Evista (Raloxifene Hydrochloride)
  • CAS No: 82640-04-8
  • Weight: 510.04422
  • Formula: C28H28ClNO4S
  • Melting Point: 143-147 deg C
  • Boiling Point: 728.2 °C at 760 mmHg
  • Density: 1.285g/cm3

Details

Evista (Raloxifene Hydrochloride)
CAS No.: 82640-04-8
Purity: 99%
Molecular Formula: C28H29NO4S
Molecular Weight: 475.5992
Apperance: White powder
Specification: USP
Uses: For osteoporosis prevention of postmenopausal women
Packing: 1kg/aluminum foil bag
Min. Order quantity: 10g
Descritpion:
Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen
receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological
actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results
in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic
pathways in other tissues (Antagonism).
Application:
May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).
Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.
Packing:
Discreet packing ways as your requirement, 100% go through.
Storage:
Store in cool and dry area and keep away from direct sunlight.
Advantage:
1. Rich experience.
Our company is a professional production leading factory in China in pharmaceutical area of many years, our products have exported to Germany, Spain, UK, USA, Australia, Middle East, and so on other country, and we have got very good feedback from our customers, we had Established long friendly relations of cooperation.
2. Great quality, purity and favourable.
Good quality is one of our secret success, welcome order the samples, MOQ just 10 grams.
3. Safe and fast delivery.
We have stock, so we can delivery quickly at the very day when receive the payment.
We have special way could ship 0.01kg to 3.5kg products a time. We offer melting powder into liquid service. And ship the liquid in special bottles.
4. Good after-sales service.

Permanent link:

Company Related ProductsView the Seller's Products

Evista (Raloxifene Hydrochloride) for anti-cancer

CAS No: 82640-04-8

Purity: 99%

Min quantity: 1000 null

Price: 1 ~ 10000 USD

Description: Evista (Raloxifene Hydrochloride) CAS No.: 82640-04-8 Purity: 99% Molecular Formula: C28H29NO4S Molecular Weight: 475.5992 Apperance: White powder Specification: USP Uses: For osteoporosis prevention of postmenopausal women Packing: 1kg/aluminum foil...

Detail more >>
Send message to this supplier

CAS No:82640-04-8 [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-<br />ylethoxy)phenyl]methanone

Ms.Lillian Cao
View the Seller's Store
- Enter between 20 to 3,000 characters. English only.
Your message must be between 20-2000 characters.English only.